MENU

Mark A. Hallman, MD, PhD

Mark A. Hallman, MD, PhD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

Assistant Professor

Treatment Focus

My primary role is as a member of the thoracic oncology program treating lung cancer, mesothelioma and cancers of the thymus.  I also treat genitourinary cancers including prostate cancer, bladder cancer, and testicular cancer.  In addition I treat lymphoma and leukemia as a member of the hematologic malignancy program.

I have had extensive training in several specialized radiation techniques:

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic Body Radiation Therapy (SBRT)
  • Prostate Brachytherapy

Treatment Philosophy

I earned doctorate degrees in both medicine and pharmacology research at the Medical University of South Carolina enrolled in the Medical Scientist Training Program. After graduation I joined Fox Chase Cancer Center for my medical residency training in the Department of Radiation Oncology. Upon completing residency I was recruited to become a member of the department faculty treating thoracic cancers, genitourinary cancers, and hematologic cancers. As part of that role, I will also be conducting research and designing clinical trials to both improve upon our current treatments and to develop new technologies in the fight against cancer.

While knowledge and expertise are important, I believe that compassion and personalized care are also essential to being an effective physician. I strive to establish trust and understanding with my patients in order to best help them complete complex and intense cancer therapies in order to achieve the best possible outcomes.  This is an exciting time to be at Fox Chase Cancer Center. The faculty and staff at Fox Chase work as a team with the common goal of providing world class cancer treatment. Not only do I have access to state of the art technologies and cutting-edge treatments, but I also have the opportunity to develop new treatments that will improve the way we treat cancer in the future.

Educational Background

  • Residency, Department of Radiation Oncology Fox Chase Cancer Center, Philadelphia, PA, 2014
  • Department of Surgery, Medical University of South Carolina, Charleston, SC. 2010
  • MD, PhD in Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, 2009

Certifications

  • American Board of Radiology, Diplomate in Radiation Oncology, 2015

Memberships

  • American Society of Clinical Oncology
  • American Society for Therapeutic Radiology and Oncology
  • Association of Residents in Radiation Oncology
  • Radiological Society of North America

William O'Brien

Bladder Cancer

William O'Brien

Bladder Cancer

In 2015, Bill O’Brien and his wife, Jackie, celebrated 51 years of marriage. Spending time with friends is very important to them. During a weekly “breakfast club” outing in 2012 – where they meet a group of friends at a local restaurant for breakfast, Bill felt something wasn’t right with him. “I went to the rest room and I started experiencing urinary bleeding," recalls Bill, who realized he needed to see a urologist as soon as possible. Following an exam and testing, the urologist told him that something was detected on his bladder.

Research Interests

My research has focused on improving the safety and efficacy of delivering SBRT.  I will also focus on developing new ways to deliver radiation treatments to cancers that are otherwise untreatable with conventional therapies. These methods will use exciting new drug and radiation combinations to enhance the effects and targeting of radiation on tumor cells.

Selected Publications

Contemporary Trends in the Utilization of Radiotherapy in Patients with Renal Cell Carcinoma.
Shaikh T, Handorf EA, Murphy C, Kutikov A, Uzzo RG, Hallman MA, Horwitz EM, Smaldone MC.
Urology, 2015 Sep; in press (PMID:  2638611)

Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted" Zaorsky N, Hallman MA, Smaldone MC.
Annals of Translational Medicine, 2015 Oct; 3(18):274.

Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Knoepp SM, Chahal MS, Xie Y, Zhang Z, Brauner DJ, Hallman MA, Robinson SA, Han S, Imai M, Tomlinson S, Meier KE.   Mol Pharmacol, 2008 Sep;74(3):574-84.

Regulation of dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor. Hallman MA, Zhuang S, Schnellmann RG. J Pharmacol Exp Ther, 2008 May;325(2):520-8.

RasGRP1 confers the phorbol ester-sensitive phenotype to EL4 lymphoma cells. Han S, Knoepp SM, Hallman MA, Meier KE, Mol Pharmacol. 2007 Jan;71(1):314-22.

Effect of antioxidants on para-aminophenol-induced toxicity in LLC-PK1 cells. Hallman MA, Tcaho R, Tarloff JB. Toxicology, 2000 Dec;156(1):37-45.